{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T17:28:19Z","timestamp":1771954099412,"version":"3.50.1"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T00:00:00Z","timestamp":1636070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p><jats:bold>Objective:<\/jats:bold> To determine using a systematic assessment and meta-analysis if GFA injection is an appropriate substitute of propafenone for arrhythmic.<\/jats:p><jats:p><jats:bold>Design:<\/jats:bold> Conduct a systematic review and meta-analysis of randomized controlled trials.<\/jats:p><jats:p><jats:bold>Data Source:<\/jats:bold> PubMed, Web of Science, Cochrane Library, Embase, Wan-Fang Database, VIP, CNKI, and Sino Med from their inception to 7 March 2021.<\/jats:p><jats:p><jats:bold>Eligibility Criteria for Selecting Studies:<\/jats:bold> Inclusion of randomized controlled trials, which draws a comparison between GFA and propafenone. Evaluation of study integrity and conducted an extraction of independent data.<\/jats:p><jats:p><jats:bold>Main Outcome Measure:<\/jats:bold> Efficacy for supraventricular tachycardia, it is considered effective if it is reversed within 40 min (without considering recurrence); for premature ventricular beats, if they are reduced by more than 50% within 6 h.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Included in this current study are 1,294 research subjects pooled from 14 clinical studies. From the pooled assessment, GFA is demonstrated to be the equivalent of propafenone regarding the potency of effectiveness for tachycardia (RR = 1.11, 95% CI: 0.96, 1.28, <jats:italic>P<\/jats:italic> = 0.15). The subset analysis indicated that GFA has a better effect on premature ventricular beats (RR = 1.35, 95% CI: 1.07, 1.70, <jats:italic>P<\/jats:italic> = 0.01) and a similar effect on supraventricular tachycardia (RR = 1.07, 95% CI: 0.98, 1.12, <jats:italic>P<\/jats:italic> = 0.21). GFA effectiveness is lesser than propafenone in the case of mean converting time (WMD = \u22121.18, 95% CI: \u22122.30, \u22120.07, <jats:italic>P<\/jats:italic> = 0.04), systolic blood pressure (WMD = \u22123.53, 95% CI: \u22126.97, \u22120.09, <jats:italic>P<\/jats:italic> = 0.04), and QRS complex (WMD = \u22123.82, 95% CI: \u22126.96, \u22120.69, <jats:italic>P<\/jats:italic> = 0.02). Both GFA and propafenone have identical effects for diastolic blood pressure, heart rate, P-R interval, and QTc interval.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> A meta-analysis of RCTs was performed across 14 clinical trials, whereby 1,294 patients are used as research subjects. From the results, it is revealed that the effect exhibited by GFA injection is similar to the propafenone injection when treating premature ventricular beats or supraventricular tachycardia. Nevertheless, in certain academic disciplines, it was found that GFA is safer and beneficial compared to propafenone. Based on facts from relevant studies, GFA is deemed applicable during clinical practice.<\/jats:p><jats:p><jats:bold>Systematic Review Registration:<\/jats:bold><jats:ext-link>https:\/\/www.inplasy.com\/inplasy-2021-3-0077\/<\/jats:ext-link>, identifier: INPLASY202130077.<\/jats:p>","DOI":"10.3389\/fcvm.2021.723932","type":"journal-article","created":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T10:05:32Z","timestamp":1636106732000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["The Efficacy Comparison Between Guan-Fu Base A Hydrochloric Injection vs. Propafenone Hydrochloric Injection in the Treatment of Arrhythmia: Systemic Review and Meta-Analysis"],"prefix":"10.3389","volume":"8","author":[{"given":"Jinming","family":"Song","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaofeng","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyue","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zongpei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,11,5]]},"reference":[{"key":"B1","first-page":"S35","article-title":"\u201cActual del tratamiento farmacol\u00f3gico de las arritmias\u201d Current status of pharmacologic treatment of arrhythmia","volume-title":"Arch Cardiol Mex.","author":"C\u00e1rdenas","year":"2002"},{"key":"B2","first-page":"731","article-title":"Arrhythmias, sudden death, and syncope","author":"Bonow","year":"2000"},{"key":"B3","first-page":"247","article-title":"Anti-arrhythmic effects of GFA","volume":"4","author":"Chen","year":"1983","journal-title":"Acta Pharm Sin."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.3321\/j.issn:1003-3734.2006.22.009","article-title":"Effects of Guanfu base A hydrochloride on heart L-type calcium channel of rat ventricular myocytes","volume":"15","author":"Gao","year":"2006","journal-title":"Chin J New Drugs."},{"key":"B5","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3760\/cma.j.issn.1007-6638.2007.01.012","article-title":"Blocking effects of guanfu base A on sodium channel in isolated guinea pig ventricular myocytes","volume":"11","author":"Li","year":"2007","journal-title":"Chin J Cardiac Arrhyth."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1056\/NEJMcp1111259","article-title":"Evaluation and initial treatment of supraventricular tachycardia","volume":"367","author":"Link","year":"2012","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/s0735-1097(97)00422-1","article-title":"Paroxysmal supraventricular tachycardia in the general population","volume":"31","author":"Orejarena","year":"1998","journal-title":"J Am Coll Cardiol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ahj.2020.12.012","article-title":"Trends in health care resource use and expenditures in patients with newly diagnosed paroxysmal supraventricular tachycardia in the United States","volume":"233","author":"Chew","year":"2021","journal-title":"Am Heart J."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1056\/NEJMcp051145","article-title":"Supraventricular Tachycardia","volume":"354","author":"Delacr\u00e9taz","year":"2006","journal-title":"N Engl J Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1056\/NEJMra1615244","article-title":"Catheter ablation of ventricular arrhythmias","volume":"380","author":"Shivkumar","year":"2019","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s00399-020-00664-0","article-title":"Acute management of ventricular tachycardia","volume":"31","author":"Deneke","year":"2020","journal-title":"Herzschr Elektrophys."},{"key":"B12","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.tcm.2018.09.014","article-title":"Treatment of ventricular arrhythmias: what's new?","volume":"29","author":"Markman","year":"2019","journal-title":"Trends Cardiovasc Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.tcm.2018.10.006","article-title":"My approach to the patient with ventricular arrhythmia and no structural heart disease","volume":"29","author":"Issa","year":"2019","journal-title":"Trends Cardiovasc Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"B15","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3760\/j:issn:0253-3758.2001.02.024","article-title":"Electrophysiological effects of GFA hydrochloride injection in the human body","volume":"29","author":"Hu","year":"2001","journal-title":"Chin J Cardiol."},{"key":"B16","first-page":"81","article-title":"Guan Fu Hydrochloride injection for 52 cases of supraventricular tachycardia","volume":"23","author":"Wang","year":"2004","journal-title":"Clin Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"331","DOI":"10.3969\/j.issn.1671-7171.2002.10.003","article-title":"To Evaluate the therapeutic efficiency of GuanFu base A in ventricular arrhythmia by holter ECG and HRV","volume":"19","author":"Feng","year":"2002","journal-title":"J Clin Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"421","DOI":"10.3969\/j.issn.1009-6019.2015.03.559","article-title":"Clinical observation of GFA hydrochloride in terminating paroxysmal supraventricular tachycardia","volume":"39","author":"Liu","year":"2015","journal-title":"For All Health."},{"key":"B19","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3760\/cma.j.issn.1673-4904.2011.04.033","article-title":"Observation on therapeutic effect of GFA injection for Supraventricular tachycardia","volume":"34","author":"Kou","year":"2011","journal-title":"Chin J Postgrad Med"},{"key":"B20","first-page":"212","article-title":"Clinical study of GFA hydrochloride in terminating paroxysmal supraventricular tachycardia","volume":"22","author":"Wang","year":"2002","journal-title":"Chin J Pract Intern Med."},{"key":"B21","first-page":"784","article-title":"Observation on the efficacy and safety of GFA hydrochloride injection in terminating paroxysmal supraventricular tachycardia","volume":"27","author":"Wei","year":"2011","journal-title":"Chin J Clin Pharm and Therapeutics."},{"key":"B22","first-page":"2777","article-title":"Observation of the therapeutic effect of GFA hydrochloride in the treatment of paroxysmal atrial-ventricular reentrant tachycardia","volume":"14","author":"Wu","year":"2009","journal-title":"Modern Prevent Med."},{"key":"B23","first-page":"120","article-title":"The clinical research of Guan fu base A hydrochloride in the treatment of paroxysmal atrioventricular reentrant tachycardia","volume-title":"South Chin J Cardiol Dis","author":"Zhang","year":"2012"},{"key":"B24","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3760\/j:issn:0253-3758.2007.02.013","article-title":"Efficacy of intravenous Acehytisine Hydrochloride versus propafenone on terminating paroxysmal supraventricular tachycardia: a double-blinded, randomized multi-center study","volume":"35","author":"Gao","year":"2007","journal-title":"Chin J Cardiol."},{"key":"B25","volume-title":"Study on the difference with Guan-Fu Base A and pro propafenone in the treatment of paroxysmal supraventricular tachycardia","author":"Zheng","year":""},{"key":"B26","first-page":"220","article-title":"GFA Hydrochloride in the Treatment of Paroxysmal Atrioventricular Fracture Observation on the curative effect of recurrent tachycardia","volume-title":"Chin J Cardiol","author":"Wu","year":"2011"},{"key":"B27","doi-asserted-by":"publisher","first-page":"104","DOI":"10.3969\/j.issn.2095-6851.2019.16.139","article-title":"Clinical study of GFA hydrochloride in terminating paroxysmal supraventricular tachycardia","volume":"16","author":"Wei","year":"2019","journal-title":"Spec Health."},{"key":"B28","first-page":"91","article-title":"Comparison of the efficacy and safety of GFA hydrochloride and propafenone hydrochloride in terminating paroxysmal supraventricular tachycardia","volume":"23","author":"Wang","year":"2014","journal-title":"Clin Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"777","DOI":"10.3969\/j.issn.1672-1349.2012.07.004","article-title":"Comparative study of GFA and propafenone in the treatment of paroxysmal supraventricular tachycardia","volume":"10","author":"Zheng","year":"2012","journal-title":"Chin J Integr Med Cardio Cerebrovasc Dis."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.3969\/j.issn.1008-7664.2010.12.007","article-title":"Clinical analysis of 100 cases of paroxysmal supraventricular tachycardia treated with GFA hydrochloride in the emergency department","volume":"12","author":"Wu","year":"2010","journal-title":"ZheJiang Clin Med J."},{"key":"B31","doi-asserted-by":"publisher","first-page":"939","DOI":"10.3321\/j.issn:1003-3734.2003.11.020","article-title":"Observation of Guan-fa base A (GFA) hydrochloride injection in treatment of paroxysmal supraventricular tachycardia","volume":"12","author":"Han","year":"2003","journal-title":"Chin J New Drugs."},{"key":"B32","doi-asserted-by":"publisher","first-page":"274","DOI":"10.3969\/j.issn.0253-3685.2006.03.031","article-title":"Efficacy of GFA Hydrochloride and propafenone hydrochloride in terminating paroxysmal supraventricular tachycardia","volume":"32","author":"Geng","year":"2006","journal-title":"Jiangsu Med J."},{"key":"B33","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3760\/cma.j.issn.1007-6638.2007.04.015","article-title":"Open-labeled randomized comparison of the clinical effect of intravenous acehytisine hydrochloride versus propafenone on termination of paroxysmal supraventricular tachycardia","volume":"11","author":"Gao","year":"2007","journal-title":"Chin J Cardiac Arrhyth."},{"key":"B34","volume-title":"The clinical research of Guan fu base A hydrochloride in the treatment of paroxysmal atrioventricular reentrant tachycardia","author":"Lin","year":"2010"},{"key":"B35","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3969\/j.issn.0258-4646.2004.01.013","article-title":"Comparison of efficacy of GFA hydrochloride and propafenone hydrochloride on ventricular arrhythmias","volume":"33","author":"Chang","year":"2004","journal-title":"J Chin Med Univ."},{"key":"B36","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3969\/j.issn.1007-5062.2003.03.005","article-title":"The clinical research of GFA hydrochloride in the treatment of ventricular premature beats","volume":"22","author":"Han","year":"2003","journal-title":"J Cardio Pulmon Dis."},{"key":"B37","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3760\/cma.j.issn.1007-6638.2006.02.012","article-title":"Open-labelled randomized controlled study of guanfu base A in the treatment of ventricular arrhythmias","volume":"10","author":"Yang","year":"2006","journal-title":"Chin J Cardiac Arrhyth."},{"key":"B38","volume-title":"Double-blind randomized comparison of the clinical effect of intravenous hydrochloric guanfu base A versus propafenone on termination of paroxysmal supraventricular tachycardia","author":"Gao","year":"2004"},{"key":"B39","volume-title":"Double-blind randomized comparison of the clinical effect of intravenous hydrochloric guanfu base A versus propafenone in the treatment of chronic ventricular arrhythmias","author":"Gao","year":"2004"},{"key":"B40","doi-asserted-by":"publisher","first-page":"0361","DOI":"10.1016\/S1875-5364(15)30027-3","article-title":"Antiarrhythmic ionic mechanism of Guanfu base A\u2014Selective inhibition of late sodium current in isolated ventricular myocytes from guinea pigs","volume":"13","author":"Jin","year":"2015","journal-title":"Chin J Nat Med."},{"key":"B41","first-page":"234","article-title":"Effect of GFA on action potential of canine Purkinje fibers","volume":"7","author":"Zhang","year":"1986","journal-title":"Acta Pharm Sin."},{"key":"B42","doi-asserted-by":"publisher","first-page":"235","DOI":"10.11665\/j.issn.1000-5048.20150217","article-title":"Antioxidant and anti-atriaI fibrillation effects of Guanfu base A","volume":"46","author":"Guo","year":"2015","journal-title":"J China Pharm Univ."},{"key":"B43","doi-asserted-by":"publisher","first-page":"952","DOI":"10.3969\/j.issn.2001-1978.2012.07.016","article-title":"Effects and machanisms of Guanfu base-A on vasomotion of rats","volume":"28","author":"Lu","year":"2012","journal-title":"Chin Pharm Bulletin."},{"key":"B44","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3969\/j.issn.1001-6821.2000.04.012","article-title":"Evaluation of Pharmacokinetics of the Hydrochloride Guanfu Base A","volume":"16","author":"Wang","year":"2000","journal-title":"Chin J Clin Pharm."},{"key":"B45","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1124\/dmd.114.060905","article-title":"Guanfu Base A, an antiarrhythmic alkaloid of Aconitum coreanum, is a CYP2D6 inhibitor of human, monkey, and dog isoforms","volume":"43","author":"Sun","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"B46","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1056\/NEJM199002223220806","article-title":"Propafenone","volume":"322","author":"Funck-Brentano","year":"1990","journal-title":"N Engl J Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"481330","DOI":"10.3389\/fped.2020.481330","article-title":"Propafenone-induced QRS widening in a child with arrhythmogenic right ventricular cardiomyopathy: a case report and literatures review","volume":"8","author":"Chu","year":"2020","journal-title":"Front Pediatr."},{"key":"B48","first-page":"476","article-title":"Syncope, widened QRS interval, and left ventricular systolic depression: coincident with propafenone therapy for atrial fibrillation","volume":"37","author":"Samaan","year":"2010","journal-title":"Tex Heart Inst J."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.723932\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T10:06:06Z","timestamp":1636106766000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.723932\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,5]]},"references-count":48,"alternative-id":["10.3389\/fcvm.2021.723932"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2021.723932","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,5]]},"article-number":"723932"}}